California State Teachers Retirement System reduced its holdings in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 9.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,810 shares of the biopharmaceutical company’s stock after selling 3,104 shares during the period. California State Teachers Retirement System owned about 0.11% of Intercept Pharmaceuticals worth $1,672,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Stonepine Capital Management LLC purchased a new stake in Intercept Pharmaceuticals during the third quarter worth $1,080,000. National Planning Corp boosted its holdings in Intercept Pharmaceuticals by 36.2% during the third quarter. National Planning Corp now owns 71,090 shares of the biopharmaceutical company’s stock worth $4,675,000 after buying an additional 18,895 shares in the last quarter. Legal & General Group Plc boosted its holdings in Intercept Pharmaceuticals by 48.2% during the third quarter. Legal & General Group Plc now owns 8,856 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,882 shares in the last quarter. FNY Managed Accounts LLC purchased a new stake in Intercept Pharmaceuticals during the third quarter worth $417,000. Finally, Oppenheimer & Co. Inc. boosted its holdings in Intercept Pharmaceuticals by 145.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 2,833 shares in the last quarter. 73.76% of the stock is currently owned by institutional investors and hedge funds.
Intercept Pharmaceuticals Inc (NASDAQ ICPT) opened at $57.72 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. The firm has a market cap of $1,570.00, a price-to-earnings ratio of -3.90 and a beta of -2.05. Intercept Pharmaceuticals Inc has a 12-month low of $51.53 and a 12-month high of $135.59.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.48) by $0.59. The company had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The firm’s revenue for the quarter was up 697.9% on a year-over-year basis. During the same period in the prior year, the business posted ($3.59) earnings per share. equities analysts predict that Intercept Pharmaceuticals Inc will post -13.36 EPS for the current fiscal year.
A number of brokerages recently issued reports on ICPT. BidaskClub downgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Wedbush reissued a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, December 22nd. Royal Bank of Canada increased their price target on shares of Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th. Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Finally, Jefferies Group reissued a “buy” rating and set a $135.00 price target (down from $275.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $140.24.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/21/california-state-teachers-retirement-system-sells-3104-shares-of-intercept-pharmaceuticals-inc-icpt.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.